130 related articles for article (PubMed ID: 7499006)
1. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.
Kees F; Wellenhofer M; Grobecker H
Infection; 1995; 23(3):168-72. PubMed ID: 7499006
[TBL] [Abstract][Full Text] [Related]
2. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.
Burkhardt O; Borner K; Stass H; Beyer G; Allewelt M; Nord CE; Lode H
Scand J Infect Dis; 2002; 34(12):898-903. PubMed ID: 12587622
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of clarithromycin and concentrations in body fluids and bronchoalveolar cells of foals.
Womble AY; Giguère S; Lee EA; Vickroy TW
Am J Vet Res; 2006 Oct; 67(10):1681-6. PubMed ID: 17014316
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers.
Zakeri-Milani P; Valizadeh H; Ghanbarzadeh S; Nemati M
Arzneimittelforschung; 2009; 59(8):429-32. PubMed ID: 19813467
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of clarithromycin.
Rodvold KA
Clin Pharmacokinet; 1999 Nov; 37(5):385-98. PubMed ID: 10589373
[TBL] [Abstract][Full Text] [Related]
6. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration.
Mainz D; Borner K; Koeppe P; Kotwas J; Lode H
J Antimicrob Chemother; 2002 Nov; 50(5):699-706. PubMed ID: 12407126
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora.
Edlund C; Alván G; Barkholt L; Vacheron F; Nord CE
J Antimicrob Chemother; 2000 Nov; 46(5):741-9. PubMed ID: 11062193
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva.
Geerdes-Fenge HF; Goetschi B; Rau M; Borner K; Koeppe P; Wettich K; Lode H
Eur J Clin Pharmacol; 1997; 53(2):127-33. PubMed ID: 9403284
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between ritonavir and clarithromycin.
Ouellet D; Hsu A; Granneman GR; Carlson G; Cavanaugh J; Guenther H; Leonard JM
Clin Pharmacol Ther; 1998 Oct; 64(4):355-62. PubMed ID: 9797791
[TBL] [Abstract][Full Text] [Related]
12. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects.
Gotfried MH; Danziger LH; Rodvold KA
J Antimicrob Chemother; 2003 Sep; 52(3):450-6. PubMed ID: 12888589
[TBL] [Abstract][Full Text] [Related]
13. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial.
Chu S; Wilson DS; Deaton RL; Mackenthun AV; Eason CN; Cavanaugh JH
J Clin Pharmacol; 1993 Aug; 33(8):719-26. PubMed ID: 8408732
[TBL] [Abstract][Full Text] [Related]
14. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.
Rengelshausen J; Göggelmann C; Burhenne J; Riedel KD; Ludwig J; Weiss J; Mikus G; Walter-Sack I; Haefeli WE
Br J Clin Pharmacol; 2003 Jul; 56(1):32-8. PubMed ID: 12848773
[TBL] [Abstract][Full Text] [Related]
15. Studies on the bioequivalence of different strengths of tablets containing clarithromycin.
Koytchev R; Ozalp Y; Erenmemisoglu A; van der Meer MJ; Alpan RS
Arzneimittelforschung; 2004 Sep; 54(9A):588-93. PubMed ID: 15497665
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration.
Carr RA; Edmonds A; Shi H; Locke CS; Gustavson LE; Craft JC; Harris SI; Palmer R
Antimicrob Agents Chemother; 1998 May; 42(5):1176-80. PubMed ID: 9593146
[TBL] [Abstract][Full Text] [Related]
17. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration.
Tsang KW; Roberts P; Read RC; Kees F; Wilson R; Cole PJ
J Antimicrob Chemother; 1994 Feb; 33(2):289-97. PubMed ID: 8182010
[TBL] [Abstract][Full Text] [Related]
18. A PK/PD approach on the effects of clarithromycin against oral and nasal microbiota of healthy volunteers.
Del Bortolo Ruenis AP; Nobre Franco GC; Baglie S; Lopes Motta RH; Simões RP; Rosalen PL; Franco LM; Moreno RA; Abib E; Groppo FC
Int J Clin Pharmacol Ther; 2009 Feb; 47(2):96-103. PubMed ID: 19203565
[TBL] [Abstract][Full Text] [Related]
19. Clarithromycin suspension: bioequivalence studies on two different strengths.
Koytchev R; Ozalp Y; Erenmemisoglu A; van der Meer MJ; Alpan RS
Arzneimittelforschung; 2004 Sep; 54(9A):594-9. PubMed ID: 15497666
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid.
Kikuchi E; Yamazaki K; Kikuchi J; Hasegawa N; Hashimoto S; Ishizaka A; Nishimura M
Respirology; 2008 Mar; 13(2):221-6. PubMed ID: 18339019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
